Skip to main content

Advertisement

SpringerLink
Log in

Intravitreal bevacizumab for choroidal neovascularization due to pathologic myopia: long-term outcomes

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To report the long-term results of anti-vascular endothelial growth factor (VEGF) therapy for choroidal neovascularization (CNV) secondary to pathological myopia (PM).

Methods

Prospective interventional study with extension phase. Eyes affected by CNV due to PM included. All patients received an intravitreal bevacizumab injection (1.25 mg/0.05 ml) at baseline. Re-treatment was considered at each follow-up visit.

Results

The study included 101 consecutive eyes of 86 patients. All patients reached 24 months of follow-up. After 24 months, mean best-corrected visual acuity (BCVA) improvement was −0.13 (95 % CI: −0.2; −0.05) logMAR (p < 0.001) and central retinal thickness (CRT) decreased on average by 67 (95 % CI: 27; 102) μm (p < 0.01). The chorioretinal atrophy (CRA) area increased significantly after 2 years of follow-up (+7.82 mm2, p < 0.0001). Patients received 4.1 treatments, on average. Thirty-two eyes were included in the extension phase (from 24 to 60 months of follow-up). Visual acuity improved on average by −0.05 (95 % CI: −0.2; 0.1) logMAR (p > 0.05) compared to baseline. Mean reduction in CRT was 102 (95 % CI: 64;141) μm (p < 0.01). The CRA area enlarged significantly after 5 years of follow-up (+14.15 mm2, p < 0.0001). Patients received a mean of 6.7 treatments in 60 months.

Conclusions

An individualized regimen with intravitreal bevacizumab to treat CNV secondary to PM resulted in BCVA improvement and CRT decrease at 2 and 5 years. The main visual benefit was obtained between month 3 and month 24. A gradual loss of the initial BCVA gain was observed starting from month 30 to month 60 due to progression of CRA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, Futagami S, Tokoro T, Mochizuki M (2003) Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 110:1297–1305

    Article  PubMed  Google Scholar 

  2. Wong TY, Ohno-Matsui K, Leveziel N, Holz FG, Lai TY, Yu HG, Lanzetta P, Chen Y, Tufail A (2014) Myopic choroidal neovascularization: current concepts and update on clinical management. Br J Ophthalmol. doi:10.1136/bjophthalmol-2014-305131

    PubMed Central  Google Scholar 

  3. Wong TY, Ferreira A, Hughes R, Carter G, Mitchell P (2014) Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am J Ophthalmol 157:9–25

    Article  PubMed  Google Scholar 

  4. Avila MP, Weiter JJ, Jalkh AE, Trempe CL, Pruett RC, Schepens CL (1984) Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 91:1573–1581

    Article  CAS  PubMed  Google Scholar 

  5. Pece A, Brancato R, Avanza P, Camesasca F, Galli L (1994) Laser photocoagulation of choroidal neovascularization in pathologic myopia: long-term results. Int Ophthalmol 18:339–344

    Article  PubMed  Google Scholar 

  6. Virgili G, Menchini F (2005) Laser photocoagulation for choroidal neovascularisation in pathologic myopia. Cochrane Database Syst Rev 4:CD004765

    PubMed  Google Scholar 

  7. Verteporfin in Photodynamic Therapy Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial-VIP report No. 1. Ophthalmology 108:841–852

    Article  Google Scholar 

  8. Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, Lim JI, Menchini U, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld P, Schachat AP, Schmidt-Erfurth U, Sickenberg M, Singerman LJ, Slakter JS, Strong HA, Virgili G, Williams GA (2003) Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no. 3. Ophthalmology 110:667–673

    Article  PubMed  Google Scholar 

  9. Gharbiya M, Giustolisi R, Allievi F, Fantozzi N, Mazzeo L, Scavella V, Gabrieli CB (2010) Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab—a randomized controlled trial. Am J Ophthalmol 149:458–464

    Article  CAS  PubMed  Google Scholar 

  10. Baba T, Kubota-Taniai M, Kitahashi M, Okada K, Mitamura Y, Yamamoto S (2010) Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation. Br J Ophthalmol 94:864–870

    Article  PubMed  Google Scholar 

  11. Franqueira N, Cachulo ML, Pires I, Fonseca P, Marques I, Figueira J, Silva R (2012) Long-term follow-up of myopic choroidal neovascularization treated with ranibizumab. Ophthalmologica 227:39–44

    Article  CAS  PubMed  Google Scholar 

  12. Lai TY, Luk FO, Lee GK, Lam DS (2012) Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Eye 26:1004–1011

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Ikuno Y, Ohno-Matsui K, Wong TY, Korobelnik JF, Vitti R, Li T, Stemper B, Asmus F, Zeitz O, Ishibashi T, MYRROR Investigators (2015) Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study. Ophthalmology 122:1220-1227

  14. Wolf S, Balciuniene VJ, Laganovska G, Menchini U, Ohno-Matsui K, Sharma T, Wong TY, Silva R, Pilz S, Gekkieva M, RADIANCE Study Group (2014) RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 121:682–692

    Article  PubMed  Google Scholar 

  15. Tufail A, Narendran N, Patel PJ, Sivaprasad S, Amoaku W, Browning AC, Osoba O, Gale R, George S, Lotery AJ, Majid M, McKibbin M, Menon G, Andrews C, Brittain C, Osborne A, Yang Y (2013) Ranibizumab in myopic choroidal neovascularization: The 12-month results from the REPAIR study. Ophthalmology 120:1944–1945

    Article  PubMed  Google Scholar 

  16. Hamelin N, Glacet-Bernard A, Brindeau C, Mimoun G, Coscas G, Soubrane G (2002) Surgical treatment of subfoveal neovascularization in myopia: Macular translocation versus surgical removal. Am J Ophthalmol 133:530–536

    Article  PubMed  Google Scholar 

  17. Ruiz-Moreno JM, de la Vega C (2001) Surgical removal of subfoveal choroidal neovascularization in highly myopic patients. Br J Ophthalmol 85:1041–1043

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS (2007) Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularization secondary to pathological myopia. Br J Ophthalmol 91:157–160

    Article  PubMed Central  PubMed  Google Scholar 

  19. Chan WM, Lai TY, Liu DT, Lam DS (2007) Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology 114:2190–2196

    Article  PubMed  Google Scholar 

  20. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB (2009) Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 147:84–93

    Article  CAS  PubMed  Google Scholar 

  21. Monés JM, Amselem L, Serrano A, Garcia M, Hijano M (2009) Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results. Eye 23:1275–1280

    Article  PubMed  Google Scholar 

  22. Silva RM, Ruiz-Moreno JM, Rosa P, Carneiro A, Nascimento J, Rito LF, Cachulo ML, Carvalheira F, Murta JN (2010) Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results. Retina 30:407–412

    Article  PubMed  Google Scholar 

  23. Ikuno Y, Nagai Y, Matsuda S, Arisawa A, Sho K, Oshita T, Takahashi K, Uchihori Y, Gomi F (2010) Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol 149:140–146

    Article  PubMed  Google Scholar 

  24. Ruiz-Moreno JM, Montero JA (2010) Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome. Graefes Arch Clin Exp Ophthalmol 248:937–941

    Article  CAS  PubMed  Google Scholar 

  25. Gharbiya M, Cruciani F, Parisi F, Cuozzo G, Altimari S, Abdolrahimzadeh S (2012) Long-term results of intravitreal bevacizumab for choroidal neovascularisation in pathological myopia. Br J Ophthalmol 96:1068–1072

    Article  PubMed  Google Scholar 

  26. Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Bandello F (2011) Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series. Retina 31:1841–1847

    Article  CAS  PubMed  Google Scholar 

  27. Peiretti E, Vinci M, Fossarello M (2012) Intravitreal bevacizumab as a treatment for choroidal neovascularization secondary to myopia:4-year study results. Can J Ophthalmol 47:28–33

    Article  PubMed  Google Scholar 

  28. Oishi A, Yamashiro K, Tsujikawa A, Ooto S, Tamura H, Nakata I, Miyake M, Yoshimura N (2013) Long-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 251:1–7

    Article  CAS  PubMed  Google Scholar 

  29. Yodoi Y, Tsujikawa A, Nakanishi H, Otani A, Tamura H, Ojima Y, Hayashi H, Yoshimura N (2009) Central retinal sensitivity after intravitreal injection of bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol 147:816–824

    Article  CAS  PubMed  Google Scholar 

  30. Uemoto R, Nakasato-Sonn H, Kawagoe T, Akira M, Okada E, Mizuki N (2012) Factors associated with enlargement of chorioretinal atrophy after intravitreal bevacizumab for myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 250:989–997

    Article  CAS  PubMed  Google Scholar 

  31. Khanifar AA, Lederer DE, Ghodasra JH, Stinnett SS, Lee JJ, Cousins SW, Bearelly S (2012) Comparison of color fundus photographs and fundus autofluorescence images in measuring geographic atrophy area. Retina 32:1884–1891

    PubMed Central  PubMed  Google Scholar 

  32. Ruiz-Moreno JM, Montero JA, Amat-Peral P (2011) Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses. Graefes Arch Clin Exp Ophthalmol 249:595–599

    Article  CAS  PubMed  Google Scholar 

  33. Ruiz-Moreno JM, Arias L, Montero JA, Carneiro A, Silva R (2013) Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome. Br J Ophthalmol 97:1447–1450

    Article  PubMed  Google Scholar 

  34. CATT Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration. Two years results. Ophthalmology 119:1388–1398

    Article  Google Scholar 

Download references

Acknowledgments

No funding support was received for this work.

Conflict of interest

V. Sarao, D.Veritti and S. Macor declare that they have no conflict of interest in the subject matter or materials discussed in this manuscript. P.Lanzetta has acted as a consultant for Alcon, Alimera, Allergan, Bausch & Lomb, Bayer, C, Novartis, Roche and Teva.

Author information

Authors and Affiliations

  1. Department of Medical and Biological Sciences – Ophthalmology, University of Udine, Piazzale Santa Maria della Misericordia, 33100, Udine, Italy

    Valentina Sarao, Daniele Veritti, Sara Macor & Paolo Lanzetta

  2. Istituto Europeo di Microchirurgia Oculare (IEMO), Udine, Italy

    Daniele Veritti & Paolo Lanzetta

Authors
  1. Valentina Sarao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniele Veritti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sara Macor
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paolo Lanzetta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paolo Lanzetta.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sarao, V., Veritti, D., Macor, S. et al. Intravitreal bevacizumab for choroidal neovascularization due to pathologic myopia: long-term outcomes. Graefes Arch Clin Exp Ophthalmol 254, 445–454 (2016). https://doi.org/10.1007/s00417-015-3076-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-015-3076-1

Keywords

Search

Navigation